Takeda, Lilly to Challenge $9 Billion Verdict in Diabetes Drug Case - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Takeda, Lilly to Challenge $9 Billion Verdict in Diabetes Drug Case


Takeda Pharmaceuticals U.S.A., Inc. and Eli Lilly and Company announced that the companies plan to challenge the $9 billion judgment awarded by a jury in a lawsuit that alleged that Actos caused a patient’s bladder cancer.

In the case of Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al., a jury in United States District Court, Western District Louisiana found in favor of the plaintiffs and awarded $1.475 million in compensatory damages. The allocation of liability was 75% Takeda and 25% Eli Lilly. The jury also awarded $6 billion in punitive damages from Takeda and $3 billion from co-defendant, Eli Lilly.

“Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A., Inc. in a company statement. “We have empathy for the Allens, but we believe the evidence did not support a finding that Actos caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to Actos.”

"While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, senior vice president and general counsel. "Lilly disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means."

In June 2011, FDA issued a warning that there is an increase in bladder cancer risk in people who used the drug for longer than a year. The agency required that the cancer risk be added to the medication's warning label.

Judgments were entered in Takeda's favor in three previous Actos trials. Lilly was not named previously. This is the first federal case to be tried and the first in the consolidated Actos multidistrict litigation, the companies report.  Lilly copromoted Actos with Takeda from 1999 to 2006.  

Under Lilly's agreement with Takeda, Lilly will be indemnified by Takeda for its losses and expenses with respect to the US litigation and other related expenses in accordance with the terms of its indemnification agreement.  

Sources:
Takeda Pharmaceuticals U.S.A., Inc.
Eli Lilly and Company
FDA

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
10%
All of the above.
41%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here